alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,451–1,475 of 2,931 studies published 2025 · free to read (page 59 of 118) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Analytical Validation and Performance of a Blood-Based P-tau217 Diagnostic Test for Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. The journal of applied laboratory medicine 2025-05-01

Through analytical validation, this assay demonstrated robust performance across multiple lots, operators, and instruments and could be used as a tool for diagnosing AD. 5 key findings →

Participants: 1,091 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2025-06-06

With the introduction of the new causal amyloid targeting therapies, the role of biomarker-assisted diagnosis of Alzheimer disease (AD) has received a further boost. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Targeting Amyloid Pathology in Early Alzheimer's: The Promise of Donanemab-Azbt

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Pharmacy (Basel, Switzerland) 2025-02-08

Key results included a 35% slowing of decline on the Integrated Alzheimer's Disease Rating Scale (iADRS) and a 36% slowing on the Clinical Dementia Rating-Sum of Boxes (CDR-SB). 5 key findings →

Design: clinical trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Proteome Signature of Alzheimer-Like Phenotypes in Frontal Cortices From Young and Old Individuals With Down Syndrome

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Molecular neurobiology 2025-11-21

Down syndrome (DS) stands out as the most prevalent genetic contributor to intellectual disability, marked by the presence of an extra copy of chromosome 21 (HSA21). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A multivariate approach to identify association between peripheral blood DNA methylation and cerebrospinal fluid biomarkers of Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Scientific reports 2025-11-03

DNA methylation has been shown to play a crucial role in many diseases, including Alzheimer's disease (AD). 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Advance care planning and quality of life: A qualitative interview study in people with young-onset dementia and their family caregivers

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Palliative Medicine 2025-03-15

Four themes were found: sense of self, connection to others, acceptance versus resistance in the face of adversity, and orientation toward the future versus focus on the present. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer's disease and related dementias among Medicare beneficiaries aged ≥ 65 years in rural America, by Census region and select demographic characteristics: 2020

✓ Peer-reviewed alzhub usefulness score 43 out of 100. The Journal of Rural Health 2025-01-01

The study population consisted of 54 million Medicare data Fee-for-Service (FFS) and Medicare Advantage enrollees aged ≥ 65; 5.3 million beneficiaries were diagnosed with ADRD, and 16.2% (n = 861,337) of beneficiaries diagnosed with ADRD resided in rural America. 4 key findings →

Participants: 861,337 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The impact of tract‐ and county‐level segregation on 10‐year cognitive and everyday functioning outcomes of Black/African American older adults in the ACTIVE study

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia Behavior & Socioeconomics of Aging 2025-04-06

Higher segregation, indicated by lower tract and county-level interaction, was associated with better cognitive and everyday functioning levels but faster rates of decline. 5 key findings →

Participants: 695 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multilevel and multidimensional features of socioeconomic status and cognitive function in older adulthood: a cross-sectional analysis of the IGNITE study

✓ Peer-reviewed alzhub usefulness score 43 out of 100. The Lancet Regional Health - Americas 2025-08-18

[95% CI] = 0.148 [0.077-0.219]; executive function, 0.138 [0.067-0.208]; episodic memory, 0.020 [-0.051 to 0.091]; working memory, 0.128 [0.059-0.197]; visuospatial processing, 0.094 [0.023-0.164]) outperformed area-level SES in detecting cognitive deficits, and demonstrated widespread associations with poorer performance across cognitive domains. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Clinical and pathologic correlations of machine learning quantification of Aβ deposits across 3 brain regions of decedents with Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Neuropathology & Experimental Neurology 2025-12-02

Machine learning enables scalable quantification of neuropathology, offering deeper phenotyping of Alzheimer's disease (AD). 4 key findings →

Participants: 273 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The causal association between resting state intrinsic functional networks and neurodegeneration

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Brain Communications 2025-01-01

None of the genetically proxied functional network features were significantly associated with neurodegenerative outcomes (adjusted P value >0.05), despite sufficient calculated power. 5 key findings →

Participants: 47 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Dampening of Microglial Activation With Nasal Foralumab Administration in Moderate Alzheimer’s Disease Dementia

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Clinical Nuclear Medicine 2025-05-13

A 78-year-old man with moderate Alzheimer disease (AD) dementia was treated with nasal-foralumab, a fully human anti-CD3 monoclonal antibody, as part of a Food and Drug Administration expanded-access-program, based on previously demonstrated efficacy of anti-CD3 antibody in animal models. 18 F-PBR06-PET, utilizing a second-generation 18-kDa-translocator-protein ligand targeting microglia, showed diffuse reduction of radiotracer uptake throughout the brain, following 3 months of nasal-foralumab compared with baseline. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Assessing family history and approaches for identifying patients with dementia with diagnostically significant genetic findings

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Genetics in Medicine 2025-07-03

A positive family history was reported in 42% of patients in the Alzheimer disease cohort, 48% of patients in the frontotemporal dementia cohort, and 34% in those with other dementia types. 5 key findings →

Participants: 701 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Imaging‐neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN‐TU‐001 participant treated with gantenerumab

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia 2025-12-01

Overall PiB-PET uptake increased during the first two years (before ARIA-E) and decreased during the last two years (including ARIA-E episodes) (0.03±0.05 vs. -0.04±0.04 SUVR/year, p-value=0.01, Figure 2). 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events